Shkreli says he isn’t responsible for Daraprim ‘monopoly’
30-07-2020
States join antitrust suit against ‘pharma bro’ Shkreli
16-04-2020
Mark Van Scyoc / Shutterstock.com
The US Federal Trade Commission (FTC) and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim (pyrimethamine).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Martin Shkreli, competition, antitrust, drug monopoly, Daraprim, Vyera Pharmaceuticals, Turing Pharmaceuticals, Letitia James, FTC
